• 1
    Feagan B, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database System Rev, 2012 (in press).
  • 2
    Feagan B, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database System Rev, 2012 (in press).
  • 3
    Kruis W, Kiudelis G, Rácz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009; 58: 233240.
  • 4
    Kane SV, Brixner D, Rubin DT, et al. The challenge of compliance and persistence: focus on ulcerative colitis. J Manag Care Pharm. 2008; 14( 1 Suppl A): s212.
  • 5
    Beaulieu DB, Schwartz DA. Medication persistence in patients with ulcerative colitis: meeting the challenges and improving patient outcomes CME. MedScape CME Gastroenterology. Posted 12/22/2009.
  • 6
    Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003; 114: 3943.
  • 7
    Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol. 2001; 96: 29292933.
    Direct Link:
  • 8
    Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol. 2007; 102: 14171426.
    Direct Link:
  • 9
    Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J. 1955; 4947: 10411048.
  • 10
    Higgins JPT, Altman DG (eds.). Assessing risk of bias in included studies. In: Higgins JPT, Green S, editorss. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from
  • 11
    Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924.
  • 12
    Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analysis. BMJ. 2003; 327: 557560.
  • 13
    Kane SV, Solomon DM, Palmen M, et al. MMX® mesalamine 2.4g/day maintains clinical remission in patients with mild to moderate ulcerative colitis, irrespective of prior treatment. Gastroenterology. 2010; 138( 5 Suppl 1): S700.
  • 14
    Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001; 15: 5362.
  • 15
    Andus T, Kocjan A, Muser M, et al. Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. Inflamm Bowel Dis. 2010; 16: 19471956.
  • 16
    Pedersen G, Brynskov J. Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. Am J Gastroenterol. 2010; 105: 15951603.
  • 17
    Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4: 7983.
  • 18
    Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997; 11: 10531057.
  • 19
    Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 18671871.
  • 20
    Ngô Y, Gélinet JM, Ivanovic A, et al. [Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial.] Gastroenterol Clin Biol. 1992; 16: 782786.
  • 21
    Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991; 32: 929931.
  • 22
    Campieri M, Gionchetti P, Belluzzi A, et al. 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol. 1988; 10: 406409.
  • 23
    Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987; 92: 18941898.
  • 24
    Powell-Tuck J, MacRae KD, Healy MJ, et al. A defence of the small clinical trial: evaluation of three gastroenterological studies. Br Med J (Clin Res Ed). 1986; 292: 599602.
  • 25
    Gross V, Bunganic I, Mikhailova TL, et al. Efficacy and tolerability of a once daily treatment with budesonide capsules versus mesalamine granules for the treatment of active ulcerative colitis: a randomized, double-blind, double-dummy, multicenter study. Gastroenterology. 2009; 136( 5 Suppl 1): A15.
  • 26
    D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006; 24: 10871097.
  • 27
    Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 6675.
  • 28
    Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95102.
  • 29
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003; 1: 170173.
  • 30
    Kane S, Holderman W, Jacques P, et al. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence. 2008; 2: 253258.
  • 31
    Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893902.
  • 32
    Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009; 7: 762769.
  • 33
    Prantera C, Kohn A, Campieri M, et al. Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther. 2009; 30: 908918.
  • 34
    Sandborn WJ, Korzenik J, Lashner B, et al. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology. 2010; 138: 12861296.
  • 35
    Kruis W, Jonaitis L, Pokrotnieks J, et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment Pharmacol Ther. 2011; 33: 313322.
  • 36
    Hawthorne AB, Stenson R, Gillespie D, et al. Once daily mesalazine as maintenance therapy for ulcerative colitis (UC): a one-year single-blind randomised trial. Gastroenterology. 2011; 140( 5 Suppl 1): S65.
  • 37
    Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2006; 23: 577585
  • 38
    Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs — do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med. 1995; 332: 11251131.
  • 39
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 18: 191198.
  • 40
    Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol. 1999; 94: 17331742.
    Direct Link:
  • 41
    Brixner D, Magowan S, Accortt N. Evaluation of prescription refill patterns based on daily dosing regimen and pill load for calcium channel blockers. Academy of Managed Care Pharmacy Annual Meeting. San Diego, CA; 2007.
  • 42
    Magowan S, Kane S, Lange JL. 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens. Am J Gastroenterol. 2006; 101: S447 (abstract 1144).